These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 22546330)

  • 1. Invasive Escherichia coli vaccines expressing Brucella melitensis outer membrane proteins 31 or 16 or periplasmic protein BP26 confer protection in mice challenged with B. melitensis.
    Gupta VK; Radhakrishnan G; Harms J; Splitter G
    Vaccine; 2012 Jun; 30(27):4017-22. PubMed ID: 22546330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and evaluation as vaccines in mice of Brucella melitensis Rev.1 single and double deletion mutants of the bp26 and omp31 genes coding for antigens of diagnostic significance in ovine brucellosis.
    Cloeckaert A; Jacques I; Grilló MJ; Marín CM; Grayon M; Blasco JM; Verger JM
    Vaccine; 2004 Jul; 22(21-22):2827-35. PubMed ID: 15246618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization of mice with a novel recombinant molecular chaperon confers protection against Brucella melitensis infection.
    Ghasemi A; Jeddi-Tehrani M; Mautner J; Salari MH; Zarnani AH
    Vaccine; 2014 Nov; 32(49):6659-66. PubMed ID: 25240754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological responses and protective efficacy against Brucella melitensis induced by bp26 and omp31 B. melitensis Rev.1 deletion mutants in sheep.
    Jacques I; Verger JM; Laroucau K; Grayon M; Vizcaino N; Peix A; Cortade F; Carreras F; Guilloteau LA
    Vaccine; 2007 Jan; 25(5):794-805. PubMed ID: 17070627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo immunogenicity assessment and vaccine efficacy evaluation of a chimeric tandem repeat of epitopic region of OMP31 antigen fused to interleukin 2 (IL-2) against Brucella melitensis in BALB/c mice.
    Nazifi N; Tahmoorespur M; Sekhavati MH; Haghparast A; Behroozikhah AM
    BMC Vet Res; 2019 Nov; 15(1):402. PubMed ID: 31703683
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Verdiguel-Fernández L; Oropeza-Navarro R; Ortiz A; Robles-Pesina MG; Ramírez-Lezama J; Castañeda-Ramírez A; Verdugo-Rodríguez A
    J Microbiol Biotechnol; 2020 Apr; 30(4):497-504. PubMed ID: 31986561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of immunogenicity and protective activity in BALB/c mice of the 25-kDa major outer-membrane protein of Brucella melitensis (Omp25) expressed in Escherichia coli.
    Bowden RA; Cloeckaert A; Zygmunt MS; Dubray G
    J Med Microbiol; 1998 Jan; 47(1):39-48. PubMed ID: 9449948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination with the recombinant Brucella outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4+ T helper 1 response that protects against Brucella melitensis infection.
    Cassataro J; Estein SM; Pasquevich KA; Velikovsky CA; de la Barrera S; Bowden R; Fossati CA; Giambartolomei GH
    Infect Immun; 2005 Dec; 73(12):8079-88. PubMed ID: 16299302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy evaluation of live Escherichia coli expression Brucella P39 protein combined with CpG oligodeoxynucleotides vaccine against Brucella melitensis 16M, in BALB/c mice.
    Al-Mariri A; Mahmoud NH; Hammoud R
    Biologicals; 2012 Mar; 40(2):140-5. PubMed ID: 22296786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved immunogenicity and protective efficacy of a divalent DNA vaccine encoding Brucella L7/L12-truncated Omp31 fusion protein by a DNA priming and protein boosting regimen.
    Golshani M; Rafati S; Siadat SD; Nejati-Moheimani M; Shahcheraghi F; Arsang A; Bouzari S
    Mol Immunol; 2015 Aug; 66(2):384-91. PubMed ID: 25968974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant Lactococcus Lactis Displaying Omp31 Antigen of Brucella melitensis Can Induce an Immunogenic Response in BALB/c Mice.
    Shirdast H; Ebrahimzadeh F; Taromchi AH; Mortazavi Y; Esmaeilzadeh A; Sekhavati MH; Nedaei K; Mirabzadeh E
    Probiotics Antimicrob Proteins; 2021 Feb; 13(1):80-89. PubMed ID: 32661939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A DNA vaccine coding for the Brucella outer membrane protein 31 confers protection against B. melitensis and B. ovis infection by eliciting a specific cytotoxic response.
    Cassataro J; Velikovsky CA; de la Barrera S; Estein SM; Bruno L; Bowden R; Pasquevich KA; Fossati CA; Giambartolomei GH
    Infect Immun; 2005 Oct; 73(10):6537-46. PubMed ID: 16177328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new candidate vaccine for human brucellosis based on influenza viral vectors: a preliminary investigation for the development of an immunization schedule in a guinea pig model.
    Bugybayeva D; Kydyrbayev Z; Zinina N; Assanzhanova N; Yespembetov B; Kozhamkulov Y; Zakarya K; Ryskeldinova S; Tabynov K
    Infect Dis Poverty; 2021 Feb; 10(1):13. PubMed ID: 33593447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A recombinant subunit vaccine based on the insertion of 27 amino acids from Omp31 to the N-terminus of BLS induced a similar degree of protection against B. ovis than Rev.1 vaccination.
    Cassataro J; Pasquevich KA; Estein SM; Laplagne DA; Velikovsky CA; de la Barrera S; Bowden R; Fossati CA; Giambartolomei GH; Goldbaum FA
    Vaccine; 2007 May; 25(22):4437-46. PubMed ID: 17442465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The recombinant Omp31 from Brucella melitensis alone or associated with rough lipopolysaccharide induces protection against Brucella ovis infection in BALB/c mice.
    Estein SM; Cassataro J; Vizcaíno N; Zygmunt MS; Cloeckaert A; Bowden RA
    Microbes Infect; 2003 Feb; 5(2):85-93. PubMed ID: 12650766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of outer membrane vesicles from Brucella melitensis and protection induced in mice.
    Avila-Calderón ED; Lopez-Merino A; Jain N; Peralta H; López-Villegas EO; Sriranganathan N; Boyle SM; Witonsky S; Contreras-Rodríguez A
    Clin Dev Immunol; 2012; 2012():352493. PubMed ID: 22242036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of Brucella melitensis Rev.1 ΔOmp19 mutants with DIVA feature and comparison of their efficacy against three commercial vaccines in a mouse model.
    Uslu A; Erganis O
    Mol Immunol; 2021 May; 133():44-52. PubMed ID: 33631554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of specific cell-mediated immune responses and protection in BALB/c mice by vaccination with outer membrane vesicles from a Brucella melitensis human isolate.
    Bagheri Nejad R; Yahyaraeyat R; Es-Haghi A; Nayeri Fasaei B; Zahraei Salehi T
    APMIS; 2019 Dec; 127(12):797-804. PubMed ID: 31514254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of immune response in mice with a DNA vaccine encoding outer membrane protein (omp31) of Brucella melitensis 16M.
    Gupta VK; Rout PK; Vihan VS
    Res Vet Sci; 2007 Jun; 82(3):305-13. PubMed ID: 17014873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization of mice with recombinant S-adenosyl-L-homocysteine hydrolase protein confers protection against Brucella melitensis infection.
    Yang Y; Yin J; Guo D; Lang X; Wang X
    FEMS Immunol Med Microbiol; 2011 Mar; 61(2):159-67. PubMed ID: 21166726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.